Inequities in access to biologic and synthetic DMARDs across 46 European countries.
about
Biosimilars in rheumatology: understanding the rigor of their developmentKey design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an exampleThe changing landscape of biosimilars in rheumatologyRate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesAccess to an optimal treatment. Current situationThe safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.Use of data from multiple registries in studying biologic discontinuation: challenges and opportunitiesThe Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesTen years of biosimilars in Europe: development and evolution of the regulatory pathways.Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal studyThe global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases.Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols.Demonstrating Value for Biosimilars: A Conceptual Framework.The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesAssessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across GermanyComparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyThe New and Old Europe: East-West Split in Pharmaceutical Spending.Commentary: Patient Cost Sharing and Medical Expenditures for the ElderlyA phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FuturePatient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe.Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.A review of CT-P13: an infliximab biosimilar.Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries.Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceThe optimal combination therapy for the treatment of early rheumatoid arthritis.Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.Use of biologics for psoriasis in Central and Eastern European countries.Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.Biosimilars for the management of rheumatoid arthritis: economic considerations.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.Burden of rheumatoid arthritis in the Nordic region, 1990-2015: a comparative analysis using the Global Burden of Disease Study 2015.Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region.
P2860
Q26744773-F09B6BC9-0D89-445C-A259-4C1075995186Q26766368-4FD2D138-14F0-4959-A2E3-F74FC9794BE3Q26766515-4DFB93FB-1081-45C1-93D0-B48A6693AADAQ26778600-CDF4CBE2-3397-4DCF-B15E-641EF72A2E82Q26799304-E2EFE14D-DF2D-4A6B-9860-29591E383E37Q30397234-B5C67719-7A1F-4B2A-B8D5-2358B51390A7Q30678187-560328F1-DA4C-474A-A3D3-2CD49E5E28CFQ33665611-E553ED2E-BCE8-4BEA-AD96-9DA53E159D1CQ33713947-538B8454-CA0A-4947-B9F3-3A6B8267E0D6Q33730376-770DB760-790F-4876-BF99-F4B98B5A3C62Q34013509-BE5DB01C-FC12-4E5C-8FCA-86BA19887765Q35533763-837A8494-48FF-4B3F-AFA4-7EB5D44749BAQ35592110-A8DA4682-547D-404F-A515-FD326F5B4DA1Q35668071-79A225D8-5234-4FDC-9D92-49E8113081CFQ35741271-92D960AF-E3F2-44E9-B765-E0E9F965E7ACQ36183803-4AD5BE5A-CCDD-4EDC-91F1-DB09E246CE9AQ36347183-62AC6F03-1352-433B-9331-5F34FD490721Q36485893-ADCF8720-3B73-416C-99B9-B685C282B230Q36633030-9CAC1332-38A6-4507-9A5B-FD0793CD648EQ36743290-6A5D46E3-F744-44F2-BA4A-ADB8B1BB7E78Q36759817-507DE9AE-4685-4648-AC25-0F778A681126Q37135584-9E76A426-F211-4A89-B490-041B4C84740CQ37453045-30C45D03-00B7-4FD9-B030-EF4584D62118Q37597661-11738E6C-6678-457B-8BE6-224CFAB381FEQ37616966-6B137FCF-F37B-4F54-9128-FFBF4E7860DCQ38203821-815EE4B0-C245-4FD3-AD63-5931D72424B4Q38212141-7C157155-D0E0-46E1-A348-6485F88B4D48Q38365041-C58FAE99-97EF-4991-AEDD-D009A129A145Q38476881-2B14CBBB-F761-4631-A486-C42BC0DCE609Q38522457-3D548FF4-F9D9-456E-81F9-AF85F3E13743Q38533964-E2160EA8-50EF-4931-9F85-C867B4E5D3E7Q38581304-3EC7272F-9A5D-4468-8320-9C608A29F318Q38586836-403AEC0D-A0DE-49A0-B11C-95FD7E9A1980Q38591275-F2D3E456-994B-4881-BFD7-E6D3D3CBE9D0Q38591281-D2176ADD-CB31-4E54-BDEF-704854348FE5Q38592363-3A62BF4C-7635-4CF7-A3AA-D0AFF2D8981EQ38610858-544FD6B3-45B2-4A85-A269-BFCC87A599E3Q38647394-73FEFBC0-4F54-4601-8609-35F815A0FC46Q38647397-A41AFC6F-FFC0-4FB4-806B-7C07E83F34B5Q38663329-D9CD6013-4E4E-4844-A36E-8547943B0E9C
P2860
Inequities in access to biologic and synthetic DMARDs across 46 European countries.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Inequities in access to biologic and synthetic DMARDs across 46 European countries.
@en
Inequities in access to biologic and synthetic DMARDs across 46 European countries.
@nl
type
label
Inequities in access to biologic and synthetic DMARDs across 46 European countries.
@en
Inequities in access to biologic and synthetic DMARDs across 46 European countries.
@nl
prefLabel
Inequities in access to biologic and synthetic DMARDs across 46 European countries.
@en
Inequities in access to biologic and synthetic DMARDs across 46 European countries.
@nl
P2093
P2860
P50
P1476
Inequities in access to biologic and synthetic DMARDs across 46 European countries.
@en
P2093
Annelies Boonen
Polina Putrik
Tuulikki Sokka
Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-202603
P407
P577
2013-03-06T00:00:00Z